What Will Happen to Arcus Biosciences, Inc. (RCUS) Next? The Stock Just Increased A Lot

April 16, 2018 - By Maria Brooks

The stock of Arcus Biosciences, Inc. (NYSE:RCUS) is a huge mover today! The stock increased 8.45% or $1.29 during the last trading session, reaching $16.56. About 152,142 shares traded. Arcus Biosciences, Inc. (NYSE:RCUS) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 5 months positive chart setup for the $724.51M company. It was reported on Apr, 16 by Barchart.com. We have $17.06 PT which if reached, will make NYSE:RCUS worth $21.74 million more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company has market cap of $724.51 million. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.